Emcure Pharmaceuticals enterprise value

·Pharma & HealthChart ›
MultiplesEnterprise valuePer share
Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025
35,359——
137137232
26.626.6195
1,2041,204732
36,453——
1,0671,067500
₹1,922.71——
6,1816,1815,373
19.5%19.5%13.6%
0.03×——
3.76×——
18.41×——
23.44×——
92.09×——
Reference items — trailing FY values
9,6839,2047,896
1,9801,8651,474
1,5551,4501,090
—944852
396396445
—370410
—548407
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

EMCURE₹1,865.00

Emcure Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersMANKINDALKEMTORNTPHARMERISGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹35,359 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization——35,358.5
- Cash, Equiv & ST Investments231.6136.7136.7
+ Minority Interest195.426.626.6
+ Total Debt731.71,204.11,204.1
Enterprise Value——36,452.6
Net Debt (memo)500.11,067.41,067.4
EV per Share——1,922.71
Total Capital5,373.36,180.86,180.8
Total Debt/Total Capital13.6219.4819.48
Total Debt/EV——0.03
EV/Sales——3.76
EV/EBITDA——18.41
EV/EBIT——23.44
EV/Free Cash Flow——92.09
Reference Items — Trailing FY Values
Sales7,896.09,203.59,683.5
EBITDA1,474.41,864.51,980.3
EBIT1,090.31,449.51,555.2
Operating Cash Flow851.7943.5—
Free Cash Flow444.8395.9395.9
FCFF (free cash flow to the firm)409.8370.4—
Capital Expenditure406.9547.7—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.